Advertisement
UK markets close in 7 hours 3 minutes

  • FTSE 100

    8,290.59
    +77.10 (+0.94%)
     

  • FTSE 250

    20,365.44
    +200.90 (+1.00%)
     

  • AIM

    776.87
    +5.34 (+0.69%)
     

  • GBP/EUR

    1.1649
    -0.0010 (-0.09%)
     

  • GBP/USD

    1.2538
    -0.0026 (-0.21%)
     

  • Bitcoin GBP

    51,250.41
    -713.01 (-1.37%)
     

  • CMC Crypto 200

    1,319.08
    -46.05 (-3.37%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.58
    +0.10 (+0.13%)
     

  • GOLD FUTURES

    2,321.50
    -9.70 (-0.42%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,229.86
    +54.65 (+0.30%)
     

  • CAC 40

    8,008.28
    +11.64 (+0.15%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

U.S. says Shire subsidiaries to pay $350 mln to settle false claims act allegations

Reuters - UK Focus

WASHINGTON, Jan 11 (Reuters) - Shire PLC (Xetra: S7E.DE - news) subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act (Stuttgart: 0LW.SG - news) allegations related to unlawful methods to push "Dermagraft," a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.

"The settlement resolves allegations that Dermagraft salespersons unlawfully induced clinics and physicians with lavish dinners, drinks, entertainment and travel; medical equipment and supplies; unwarranted payments for purported speaking engagements and bogus case studies; and cash, credits and rebates, to induce the use of Dermagraft," it said. (Reporting by Washington Newsroom; Editing by Chizu Nomiyama)